MDR TB: New drugs, research and policy
- 13 June 2024
- journal article
- editorial
- Published by Elsevier in Indian Journal of Tuberculosis
- Vol. 71, S1-S2
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- A 24-Week, All-Oral Regimen for Rifampin-Resistant TuberculosisNew England Journal of Medicine, 2022
- Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant TuberculosisNew England Journal of Medicine, 2022
- TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosisTrials, 2022
- An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)American Journal of Respiratory and Critical Care Medicine, 2022